Respirology Search
Respirology Respirology
Most Read Articles
Shorter regimen an option for rifampicin-resistant TB
Pearl Toh, 30 Apr 2019
A shorter regimen comprising a seven-drug cocktail which included high-dose moxifloxacin for 9 months was noninferior to the WHO*-recommended long regimen of 20 months for treating rifampicin-resistant tuberculosis (TB), according to the STREAM** study, providing a feasible and lower-cost treatment option in resource-poor setting.
Original New Drug Application Approvals by US FDA (16 - 31 January 2017)
31 Jan 2017
New drug applications approved by US FDA as of 16 - 31 January 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Slideshow: Highlights from the American Thoracic Society 2019 (ATS 2019) International Conference

07 Jun 2019
Slideshow: Highlights from the American Thoracic Society 2019 (ATS 2019) International Conference
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Shorter regimen an option for rifampicin-resistant TB
Pearl Toh, 30 Apr 2019
A shorter regimen comprising a seven-drug cocktail which included high-dose moxifloxacin for 9 months was noninferior to the WHO*-recommended long regimen of 20 months for treating rifampicin-resistant tuberculosis (TB), according to the STREAM** study, providing a feasible and lower-cost treatment option in resource-poor setting.
Original New Drug Application Approvals by US FDA (16 - 31 January 2017)
31 Jan 2017
New drug applications approved by US FDA as of 16 - 31 January 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.